Literature DB >> 19037623

[Impact of nuclear medicine imaging techniques for lymph node surgery].

L S Freudenberg1, G Holl, S P Müller, S J Rosenbaum-Krumme, J Sciuk, A Bockisch.   

Abstract

Nuclear medicine imaging techniques allow the noninvasive in vivo visualization of cellular and subcellular molecular processes. In the context of lymph node surgery and patient management in uro-oncology, two molecular nuclear imaging techniques deserve special interest: positron emission tomography (PET) for staging, restaging, and follow-up, and preoperative identification and subsequent biopsy of the sentinel lymph node (the first lymph node in the lymphatic drainage system of the tumor). Both methods and their clinical potential are described in this review. Future trends in molecular imaging in uro-oncology are also discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19037623     DOI: 10.1007/s00120-008-1754-x

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  61 in total

1.  Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.

Authors:  Igle J de Jong; Jan Pruim; Philip H Elsinga; Willem Vaalburg; Han J Mensink
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

Review 2.  Nuclear medicine studies of the prostate, testes, and bladder.

Authors:  Suman Jana; M Donald Blaufox
Journal:  Semin Nucl Med       Date:  2006-01       Impact factor: 4.446

Review 3.  Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review.

Authors:  Kirsten Bouchelouche; Peter Oehr
Journal:  J Urol       Date:  2007-11-13       Impact factor: 7.450

4.  Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.

Authors:  Ludwig Rinnab; Felix M Mottaghy; Norbert M Blumstein; Sven N Reske; Richard E Hautmann; Kathrin Hohl; Peter Möller; Thomas Wiegel; Rainer Kuefer; Juergen E Gschwend
Journal:  BJU Int       Date:  2007-10       Impact factor: 5.588

5.  Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter.

Authors:  Keisuke Mitsuoka; Sosuke Miyoshi; Yukio Kato; Yoshihiro Murakami; Rie Utsumi; Yoshiyuki Kubo; Akihiro Noda; Yukio Nakamura; Shintaro Nishimura; Akira Tsuji
Journal:  J Nucl Med       Date:  2008-03-14       Impact factor: 10.057

6.  Intraoperative mapping of renal lymphatic drainage: technique and application in a porcine model.

Authors:  Jonathan E Bernie; Paul Zupkas; Manoj Monga
Journal:  J Endourol       Date:  2003-05       Impact factor: 2.942

7.  Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study.

Authors:  Mohsen Beheshti; Reza Vali; Peter Waldenberger; Friedrich Fitz; Michael Nader; Wolfgang Loidl; Gabriele Broinger; Franz Stoiber; Ignac Foglman; Werner Langsteger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

8.  Fluoro-18 fluorodeoxyglucose positron emission tomography/computerized tomography scans in a patient with penile cancer for appropriate therapeutic strategy.

Authors:  Metin Halac; Sabri Zincirkeser; Kerim Sönmezoglu; Sait Sager; Haydar Durak; Ilhami Uslu
Journal:  Hell J Nucl Med       Date:  2007 May-Aug       Impact factor: 1.102

9.  The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer.

Authors:  I Igerc; S Kohlfürst; H J Gallowitsch; S Matschnig; E Kresnik; I Gomez-Segovia; P Lind
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-11       Impact factor: 9.236

10.  In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems.

Authors:  Jered C Garrison; Tammy L Rold; Gary L Sieckman; Said Daibes Figueroa; Wynn A Volkert; Silvia S Jurisson; Timothy J Hoffman
Journal:  J Nucl Med       Date:  2007-07-13       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.